We are focused on bringing to market medical products that meet the needs of specialist physicians and their patients, thereby building a leading specialist healthcare business that delivers superior returns to shareholders.
We aim to expand our portfolio of marketed products through acquisition, development and commercial activities.
We established commercial operations in late 2010 and now sell our Specialty Pharmaceutical, Interventional Oncology and Interventional Vascular products direct to customers in the US.
Outside of the US our strategy is to work with partners and distributors to register and sell our products. We will keep this under review and will consider direct sales in certain territories where the economics make sense and where we have the right capabilities. We are actively pursuing an international expansion strategy for our Interventional Oncology products, in particular in Asia where high infection rates of hepatitis B and C have led to a high incidence of liver cancer.
Our research and development focus is on products that we can commercialise ourselves. We are conducting a number of exploratory studies on our interventional bead products and plan to initiate regulatory studies designed to expand the indicated uses for these products.